Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
ESPERITE N.V. (ESP) , Stabilisation before growth. | ||
By: Nasdaq / GlobeNewswire - 17 Nov 2017 | Back to overview list |
|
Esperite has taken all the necessary measures after the difficult end of the first semester. The company invests in its technology and prepares to grow again. Amsterdam, The Netherlands - 17 November 2017 Consolidated results
Consolidated revenues of the period are stable despite the common slow down of activity due to the summer. The company has increased the gross margin up to 60%. EDITDA has continued to improve during the period but remains negative. Opex is reduced by 10% compared to previous quarter.
The new clients intake is increasing on a monthly basis as well as the average selling price of the services.
The company continues its territorial expansion and explores now a new market in Ukraine with a local partner. The company expect to announce soon other developments of its commercial footprint.
The Cell Factory and Output Pharma Services, along with CryoSave BioBank and Laboratories are the key elements to this new CDMO business. About ESPERITE ESPERITE Group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and predictive medicine established in 2000. To learn more about the ESPERITE Group, or to book an interview with CEO Frédéric Amar: +31 575 548 998 - ir@esperite.com or visit the websites at www.esperite.com , www.genoma.com and www.cryo-save.com .
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Esperite N.V. via GlobeNewswire
HUG#2150442
|
||
|
||
Copyright 2017 Nasdaq / GlobeNewswire | Back to overview list |